Similar results were noticed in the OnSITE study analyzing the CTC number before and after the second cycle of treatment of the HER2-negative advanced BC patients pre-treated with anthracyclines and taxanes, who received eribulin as third-line chemotherapy show similar results [72]. This evidence concerns the gene ERBB2 and breast cancer.